(Q46362755)

English

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

0 references

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

George Fountzilas

1

object named as

George Fountzilas

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Angelos Koutras

8

object named as

Angelos K Koutras

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Dimitrios Bafaloukos

9

object named as

Dimitrios Bafaloukos

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Konstantine T Kalogeras

13

object named as

Konstantine T Kalogeras

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

A Kalogera-Fountzila

3

object named as

Anna Kalogera-Fountzila

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Georgia Karayannopoulou

7

object named as

Georgia Karayannopoulou

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Helena Linardou

6

object named as

Helena Linardou

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

author name string

Nikolaos Xiros

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Samuel Murray

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Epaminondas Samantas

10

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Christos Christodoulou

11

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Theofanis Economopoulos

12

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Paris Kosmidis

14

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

publication date

1 October 2008

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Cancer Investigation

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

26

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

8

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

784-793

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Equitable Allocation of Antiretrovirals in Resource-Constrained Countries

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Genetic pathways to primary and secondary glioblastoma

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1080%2F07357900801918611

21 January 2018

Identifiers

10.1080/07357900801918611

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18798073

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46362755&oldid=2108058012"